Efficacy and Safety of Intensive Blood Pressure Therapy Using Restricted Mean Survival Time-Insights from the SPRINT Trial.
作者信息
Krishnaswami Ashok, Peterson Eric D, Kim Dae Hyun, Goyal Parag, Rich Michael W
机构信息
Division of Cardiology, Kaiser Permanente San Jose Medical Center, San Jose, Calif; Department of Epidemiology and Biostatistics, University of California, San Francisco.
Duke Clinical Research Institute, and Division of Cardiology, Duke University Medical Center, Durham, NC.
出版信息
Am J Med. 2020 Jul;133(7):e369-e370. doi: 10.1016/j.amjmed.2019.12.050. Epub 2020 Feb 13.
Abstract
摘要
相似文献
1
Efficacy and Safety of Intensive Blood Pressure Therapy Using Restricted Mean Survival Time-Insights from the SPRINT Trial.使用受限平均生存时间的强化血压治疗的疗效与安全性——来自收缩压干预试验（SPRINT）的见解
Am J Med. 2020 Jul;133(7):e369-e370. doi: 10.1016/j.amjmed.2019.12.050. Epub 2020 Feb 13.
2
How Low Can You Go? What Can We Take From the SPRINT Trial.血压能降多低？我们能从收缩压干预试验（SPRINT）中得到什么？
S D Med. 2016 Jan;69(1):34.
3
Evidence Supporting the Blood Pressure Treatment Goal of Less Than 130/80 mm Hg.支持血压治疗目标低于130/80毫米汞柱的证据。
Hypertension. 2019 May;73(5):972-974. doi: 10.1161/HYPERTENSIONAHA.119.12804.
4
Influence of baseline systolic blood pressure on the relationship between intensive blood pressure control and cardiovascular outcomes in the Systolic Blood Pressure Intervention Trial (SPRINT).强化血压控制与心血管结局试验（SPRINT）中基线收缩压对血压控制与心血管结局关系的影响。
Clin Res Cardiol. 2019 Mar;108(3):273-281. doi: 10.1007/s00392-018-1353-9. Epub 2018 Aug 24.
5
Blood pressure management in the wake of SPRINT.SPRINT研究之后的血压管理
Cleve Clin J Med. 2016 Mar;83(3):196-8. doi: 10.3949/ccjm.83a.16015.
6
SPRINT Revisited: Updated Results and Implications.SPRINT 研究再评价：更新结果与启示
Hypertension. 2021 Dec;78(6):1701-1710. doi: 10.1161/HYPERTENSIONAHA.121.17682. Epub 2021 Nov 10.
7
SPRINT, or False Start, Toward a Lower Universal Treated Blood Pressure Target in Hypertension.收缩压干预试验（SPRINT），或高血压治疗中朝着更低的通用血压目标的错误开端。
Hypertension. 2016 Feb;67(2):266-7. doi: 10.1161/HYPERTENSIONAHA.115.06735. Epub 2015 Nov 9.
8
Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States: Projections From NHANES (National Health and Nutrition Examination Survey).在美国采用收缩压干预试验（SPRINT）强化血压治疗方案避免的潜在死亡和发生的严重不良事件：来自美国国家健康与营养检查调查（NHANES）的预测
Circulation. 2017 Apr 25;135(17):1617-1628. doi: 10.1161/CIRCULATIONAHA.116.025322. Epub 2017 Feb 13.
9
Brachial-brachial index of systolic blood pressure in the patients under anti-hypertensive therapy.接受抗高血压治疗患者的肱动脉收缩压臂间指数。
Int J Cardiol. 2014 Jul 1;174(3):802-4. doi: 10.1016/j.ijcard.2014.04.118. Epub 2014 Apr 18.
10
Hypertension treatment in the elderly: a SPRINT to the finish.老年高血压治疗：冲刺终点
Future Cardiol. 2017 Mar;13(2):99-102. doi: 10.2217/fca-2016-0078. Epub 2017 Feb 10.
引用本文的文献
1
Balancing Benefit and Harm of Intensive Blood Pressure Lowering Based on Individual Outcome Profile Analysis.基于个体结局预测分析的强化降压治疗的获益与危害平衡。
Am J Med. 2023 Dec;136(12):1196-1202.e2. doi: 10.1016/j.amjmed.2023.09.003. Epub 2023 Sep 28.
2
Restricted mean survival time versus conventional effect summary for treatment decision-making: A mixed-methods study.限制平均生存时间与常规效果总结用于治疗决策：一项混合方法研究。
J Am Geriatr Soc. 2023 Feb;71(2):528-537. doi: 10.1111/jgs.18107. Epub 2022 Nov 1.
3
Intensive Versus Standard Blood Pressure Lowering and Days Free of Cardiovascular Events and Serious Adverse Events: a Post Hoc Analysis of Systolic Blood Pressure Intervention Trial.强化降压与标准降压对无心血管事件和严重不良事件天数的影响：一项收缩压干预试验的事后分析。
J Gen Intern Med. 2022 Nov;37(15):3797-3804. doi: 10.1007/s11606-022-07753-5. Epub 2022 Aug 9.
4
Intensive versus standard blood pressure control in type 2 diabetes: a restricted mean survival time analysis of a randomised controlled trial.强化与标准血压控制对 2 型糖尿病的影响：一项随机对照试验的限制平均生存时间分析。
BMJ Open. 2021 Sep 13;11(9):e050335. doi: 10.1136/bmjopen-2021-050335.
5
Restricted mean survival time versus conventional measures for treatment decision-making.限制平均生存时间与常规措施在治疗决策中的比较。
J Am Geriatr Soc. 2021 Aug;69(8):2282-2289. doi: 10.1111/jgs.17195. Epub 2021 Apr 26.
6
Time to benefit and harm of intensive blood pressure treatment: insights from SPRINT.强化血压治疗的获益与危害时间：来自收缩压干预试验（SPRINT）的见解
Eur Heart J Qual Care Clin Outcomes. 2021 Jul 21;7(4):e1-e2. doi: 10.1093/ehjqcco/qcaa035.
本文引用的文献
1
Applying Evidence-Based Medicine to Shared Decision Making: Value of Restricted MeanSurvival Time.将循证医学应用于共同决策：受限平均生存时间的价值
Am J Med. 2019 Jan;132(1):13-15. doi: 10.1016/j.amjmed.2018.07.026. Epub 2018 Aug 1.
2
Individual and Joint Effects of Pulse Pressure and Blood Pressure Treatment Intensity on Serious Adverse Events in the SPRINT Trial.SPRINT 试验中脉压和降压治疗强度对严重不良事件的个体和联合影响。
Am J Med. 2018 Oct;131(10):1220-1227.e1. doi: 10.1016/j.amjmed.2018.05.027. Epub 2018 Jun 27.
3
A Randomized Trial of Intensive versus Standard Blood-Pressure Control.强化与标准血压控制的随机试验
N Engl J Med. 2015 Nov 26;373(22):2103-16. doi: 10.1056/NEJMoa1511939. Epub 2015 Nov 9.
Zotero 插件